BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

304 related articles for article (PubMed ID: 10966854)

  • 1. Hereditary cutaneous melanoma.
    Platz A; Ringborg U; Hansson J
    Semin Cancer Biol; 2000 Aug; 10(4):319-26. PubMed ID: 10966854
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Analysis of the CDKN2A, CDKN2B and CDK4 genes in 48 Australian melanoma kindreds.
    Flores JF; Pollock PM; Walker GJ; Glendening JM; Lin AH; Palmer JM; Walters MK; Hayward NK; Fountain JW
    Oncogene; 1997 Dec; 15(24):2999-3005. PubMed ID: 9416844
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CDKN2A mutation and deletion status in thin and thick primary melanoma.
    Cachia AR; Indsto JO; McLaren KM; Mann GJ; Arends MJ
    Clin Cancer Res; 2000 Sep; 6(9):3511-5. PubMed ID: 10999737
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CDKN2A/p16 is inactivated in most melanoma cell lines.
    Castellano M; Pollock PM; Walters MK; Sparrow LE; Down LM; Gabrielli BG; Parsons PG; Hayward NK
    Cancer Res; 1997 Nov; 57(21):4868-75. PubMed ID: 9354451
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CDKN2A mutations in Spanish cutaneous malignant melanoma families and patients with multiple melanomas and other neoplasia.
    Ruiz A; Puig S; Malvehy J; Lázaro C; Lynch M; Gimenez-Arnau AM; Puig L; Sánchez-Conejo J; Estivill X; Castel T
    J Med Genet; 1999 Jun; 36(6):490-3. PubMed ID: 10874641
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evidence for three tumor suppressor loci on chromosome 9p involved in melanoma development.
    Pollock PM; Welch J; Hayward NK
    Cancer Res; 2001 Feb; 61(3):1154-61. PubMed ID: 11221846
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [From gene to disease; from p16 to melanoma].
    Gruis NA; Bergman W
    Ned Tijdschr Geneeskd; 2000 Oct; 144(44):2100-2. PubMed ID: 11103670
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Molecular genetics of familial cutaneous melanoma.
    Haluska FG; Hodi FS
    J Clin Oncol; 1998 Feb; 16(2):670-82. PubMed ID: 9469357
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A novel type of deletion in the CDKN2A gene identified in a melanoma-prone family.
    Knappskog S; Geisler J; Arnesen T; Lillehaug JR; Lønning PE
    Genes Chromosomes Cancer; 2006 Dec; 45(12):1155-63. PubMed ID: 17001621
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Genetics of familial atypical multiple mole-melanoma (FAMMM) syndrome in The Netherlands: how far have we come?
    Gruis NA; Van der Velden PA; Bergman W; Frants RR
    Bull Cancer; 1998 Jul; 85(7):627-30. PubMed ID: 9752270
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Differential expression of p16INK4a and p16beta transcripts in B-lymphoblastoid cells from members of hereditary melanoma families without CDKN2A exon mutations.
    Rizos H; Becker TM; Holland EA; Kefford RF; Mann GJ
    Oncogene; 1997 Jul; 15(5):515-23. PubMed ID: 9247305
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Affected members of melanoma-prone families with linkage to 9p21 but lacking mutations in CDKN2A do not harbor mutations in the coding regions of either CDKN2B or p19ARF.
    Liu L; Goldstein AM; Tucker MA; Brill H; Gruis NA; Hogg D; Lassam NJ
    Genes Chromosomes Cancer; 1997 May; 19(1):52-4. PubMed ID: 9135995
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Increased risk of pancreatic cancer in melanoma-prone kindreds with p16INK4 mutations.
    Goldstein AM; Fraser MC; Struewing JP; Hussussian CJ; Ranade K; Zametkin DP; Fontaine LS; Organic SM; Dracopoli NC; Clark WH
    N Engl J Med; 1995 Oct; 333(15):970-4. PubMed ID: 7666916
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CDKN2A as a uveal and cutaneous melanoma susceptibility gene.
    Kannengiesser C; Avril MF; Spatz A; Laud K; Lenoir GM; Bressac-de-Paillerets B
    Genes Chromosomes Cancer; 2003 Nov; 38(3):265-8. PubMed ID: 14506702
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A single Mediterranean, possibly Jewish, origin for the Val59Gly CDKN2A mutation in four melanoma-prone families.
    Yakobson E; Eisenberg S; Isacson R; Halle D; Levy-Lahad E; Catane R; Safro M; Sobolev V; Huot T; Peters G; Ruiz A; Malvehy J; Puig S; Chompret A; Avril MF; Shafir R; Peretz H; Bressac-de Paillerets B
    Eur J Hum Genet; 2003 Apr; 11(4):288-96. PubMed ID: 12700603
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High- and low-penetrance cutaneous melanoma susceptibility genes.
    Fargnoli MC; Argenziano G; Zalaudek I; Peris K
    Expert Rev Anticancer Ther; 2006 May; 6(5):657-70. PubMed ID: 16759158
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Molecular alterations at chromosome 9p21 in melanocytic naevi and melanoma.
    Sini MC; Manca A; Cossu A; Budroni M; Botti G; Ascierto PA; Cremona F; Muggiano A; D'Atri S; Casula M; Baldinu P; Palomba G; Lissia A; Tanda F; Palmieri G
    Br J Dermatol; 2008 Feb; 158(2):243-50. PubMed ID: 18028495
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chromosome band 9p21 is frequently altered in malignant peripheral nerve sheath tumors: studies of CDKN2A and other genes of the pRB pathway.
    Berner JM; Sørlie T; Mertens F; Henriksen J; Saeter G; Mandahl N; Brøgger A; Myklebost O; Lothe RA
    Genes Chromosomes Cancer; 1999 Oct; 26(2):151-60. PubMed ID: 10469453
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Two p16 (CDKN2A) germline mutations in 30 Israeli melanoma families.
    Yakobson E; Shemesh P; Azizi E; Winkler E; Lassam N; Hogg D; Brookes S; Peters G; Lotem M; Zlotogorski A; Landau M; Safro M; Shafir R; Friedman E; Peretz H
    Eur J Hum Genet; 2000 Aug; 8(8):590-6. PubMed ID: 10951521
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Germline p16 mutations in familial melanoma.
    Hussussian CJ; Struewing JP; Goldstein AM; Higgins PA; Ally DS; Sheahan MD; Clark WH; Tucker MA; Dracopoli NC
    Nat Genet; 1994 Sep; 8(1):15-21. PubMed ID: 7987387
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.